Global Market Study on Rosacea Therapeutics: Emergence of Laser Therapy and Dermabrasion Trending the Global Market


Rosacea Treatment  Market
  • Published On : Nov-2018 |
  • Pages : 180 Pages |
  • Format :

A recent market study published by Persistence Market Research – “Rosacea Therapeutics Market: Global Industry Analysis 2013-2017 & Forecast 2018-2026” consists a comprehensive assessment of the most important market dynamics. On conducting a thorough research on the historic as well as current growth parameters of the Rosacea therapeutics market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the Rosacea therapeutics market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the Rosacea therapeutics market in the upcoming years. The report provides detailed information about the current and future growth prospects of the Rosacea therapeutics market in the most comprehensive way for the better understanding of readers.

Chapter 1 – Executive Summary

The report commences with the executive summary of the Rosacea therapeutics market report, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the Rosacea therapeutics market.

Chapter 2 – Market Overview

Readers can find detailed taxonomy and the definition of the Rosacea therapeutics market in this chapter, which helps readers to understand the basic information about the Rosacea therapeutics market dynamics, supply chain, cost structure, pricing analysis, list of key distributor and suppliers, list of key market participants included in the report.

Chapter 3 – Global Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026, By Drug Class

Based on the drug class, the Rosacea therapeutics market is segmented into antimicrobials, alpha agonists, retinoid and others. In this chapter, readers can find information about key trends and developments in the Rosacea therapeutics market and market attractive analysis based on the antimicrobials, alpha agonists, retinoid and others. In this chapter, readers can find information about key trends and developments in the Rosacea therapeutics market and market attractive analysis based on the drug class for each region.

Chapter 4 – Global Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026, By Distribution Channel

Based on the distribution channel, the rosacea therapeutics market is segmented into institutional sales, and retail sales. In this chapter, readers can find information about key trends and developments in the Rosacea therapeutics market and market attractive analysis based on distribution channel. In this chapter, readers can find information about key trends and developments in the Rosacea therapeutics market and market attractive analysis based on the distribution channel for each region.

Chapter 5 – Global Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026, By Region

This chapter explains how the Rosacea therapeutics market will grow across various geographic regions, such as North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa (MEA).

Chapter 6 – North America Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026

This chapter includes detailed analysis of the growth of the North America Rosacea Therapeutics market along with the country-wise assessment including the U.S. and Canada. readers can also find regional trends, regulations, and market growth based on drug class, distribution channel and country of Rosacea therapeutics in the North American region.

Chapter 7 – Latin America Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026

Readers can find detailed information about factors such as, pricing analysis, and regional trends that are impacting the growth of the Latin America Rosacea therapeutics market. This chapter also includes the growth prospects of the Rosacea therapeutics market in the Latin America region.

Chapter 8 – Europe Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026

Important growth prospects of the Rosacea therapeutics market based on its drug class, distribution channel in several European countries, such as Germany, France, Italy, Spain, U.K., Russia and Rest of Europe is included in this chapter.

Chapter 9 – APEC Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026

Growth prospects of Rosacea therapeutics in the APEC region that are the prime subject of assessment of the APEC Rosacea therapeutics market in this chapter. Readers can find thorough information about the growth parameters of the APEC Rosacea therapeutics market during the period 2018-2026.

Chapter 10 – MEA Rosacea Therapeutics Market Analysis 2013-2017 & Forecast 2018-2026

This chapter provides information on how the Rosacea therapeutics market will grow in the MEA region during the period 2013-2026.

Chapter 11 – Competition Landscape, Company Share and Company Profiles

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the Rosacea therapeutics market along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Market players featured in the report include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, Janssen Pharmaceuticals, Inc.

Chapter 12 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 13 – Research Methodology

This chapter helps readers to understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the Rosacea therapeutics market.

Bimodal Nature of Oral and Tropical Rosacea Therapeutics

The rosacea therapeutics market is highly fragmented owing to patent expiry and generic penetration by vendors who are competing on the basis of market penetration and pricing. However, the consolidated nature of the rosacea therapeutics market has increased the profitability of the business owing to advanced formulations. The growing awareness regarding rosacea therapeutics and surging geriatric population have created lucrative growth opportunities for the players operating in the rosacea therapeutics market. Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Foamix Pharmaceuticals Ltd., and Bayer AG hold more than 50% revenue share in the global rosacea therapeutics market. The growth of the global rosacea therapeutics market is primarily driven by growing prevalence of rosacea and geriatric population. The development of healthcare infrastructure around the world is also expected to drive the growth of the rosacea therapeutics market.

Growing Geriatric Population and Screening Rates

The increasing screening rates as well as geriatric population are the critical drivers of the rosacea therapeutics market. According to the National Rosacea Society, rosacea affects an estimated 415 million people worldwide. The general population suffering from rosacea are estimated to be 2.5–5.5%. Extrapolating based on an estimated global population of 7.6 billion, yields a number of 181,640,000 to 414,960,000 people suffering from rosacea worldwide. The statistics also state that 16 million Americans suffer from the signs and symptoms of rosacea, and millions more may be in temporary remission. According to the Canadian Dermatology Association, rosacea affects over three million Canadians. Thus, the growing number of people being affected from rosacea is projected to surge the growth of the market for rosacea therapeutics.

Intense Competition from Off-label Pharmaceuticals

The rosacea therapeutics market is being increasingly by the advent of off label drugs such as Botulinum toxin used only for specialist use in refractory cases. Other off label drugs used are erythromycin, clindamycin, permethrin and others employed occasionally without any recommendations and validation for effectiveness and efficacy

The use of these off label drugs for the treatment of Rosacea has been taking place despite warnings from the European Medicine Agencies and the Food and Drug Administration due to poor validation and lack of efficiency and effectiveness.

New Drug Development and Increasing Approvals of Rosacea Therapeutics

There has been a host of approvals for Rosacea therapeutics by FDA and other agencies which has generated a lot of market enthusiasm. A topical form of the alpha-2 agonist brimonidine was approved by the FDA in August 2013 for treatment of erythema associated with rosacea. Another topical alpha agonist, oxymetazoline, was approved in 2017 for persistent facial erythema associated with rosacea in adults. Topical ivermectin (Soolantra) has been approved by the FDA for treatment of the inflammatory lesions of rosacea. In 2017, FDA approved RHOFADE (Oxymetazoline Hydrochloride) Cream, 1% For The Topical treatment of persistent facial erythema associated with rosacea in adults 19, 2017. Food and Drug Administration (FDA) also granted tentative approval for Zenavod (doxycycline) capsules for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults.

rosacea therapeutics market

Growing Exposure to Trigger Factors Owing to Urbanization and Industrialization

Rosacea trigger factors include hot drinks and spicy foods, alcohol, extremes of temperature, sunlight or wind, emotions, exercise, cosmetics, drugs that dilate blood vessels, including some blood pressure medications and others. There has been a growing exposure to these triggers owing to the effects of urbanization and industrialization

The growing adoption of cosmetics and the hypertensive population also drives a large market for rosacea. Rosacea incidence also increases with age as most patients are over age 30. The growing number of young who smoke also drives the incidence rates of Rosacea.

The growing healthcare infrastructure as well as healthcare expenditure of Europe, which accounts to average 10% of GDP, are factors driving the growth of the Europe Rosacea therapeutics market. Other European nations with a sizeable Rosacea therapeutics market are France, the U.K., Italy and Spain.

Competitive Landscape

Competition section of the Rosacea therapeutics market features profiles of key players operating in the industry based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Some of the key players operating in the Rosacea therapeutics market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Foamix Pharmaceuticals Ltd., Bayer A and Janssen Pharmaceuticals, Inc.

Definition

Rosacea is a common skin condition characterized by redness and visible blood vessels on the face. The nose and cheeks are the most affected regions. The signs and symptoms of Rosacea are small, red, pus-filled bumps which may flare up periodically. About half the patients experience eye dryness, irritation and swollen, reddened eyelids. Other symptoms include enlarged nose, thickening the skin on the nose, (rhinophyma). Rosacea predominantly affects middle-aged women having fair skin.

About the Report

FMI conducted a research study on Rosacea therapeutics market for the forecast period 2018 to 2026. The Rosacea therapeutics market report offers a comprehensive evaluation of the business opportunities prevailing in the Rosacea therapeutics market along with insights on the Rosacea therapeutics consumption trend, disease incidences, and awareness level for Rosacea therapeutics market competition. The report elaborates on the macroeconomic factors influencing the dynamics of Rosacea therapeutics market and its futuristic potential.

Segmentation

The report offers a comprehensive taxonomy of Rosacea therapeutics market based on drug class, distribution channels and region. The drug class segment of the Rosacea therapeutics market includes antimicrobials, alpha agonists, retinoid and others. The distribution channel segment of the Rosacea therapeutics market includes institutional sales and retail sales. The institutional sales includes hospital pharmacies, and clinics. The retail sales includes retail sales, retail pharmacies, drug stores and mail order pharmacies.

The Rosacea therapeutics market has been analyzed across regions of North America, Latin America, Europe, Asia Pacific and MEA.

Additional Questions Answered

Some of the additional questions addressed in this report on Rosacea therapeutics market-

  • What is the revenue potential of point of care Rosacea therapeutics across regions of North America and Europe?
  • Who are the key competitors and what are their portfolios in Rosacea therapeutics market?
  • What are major challenges influencing the growth of Rosacea therapeutics market?
  • How intervention from regulatory authority is shaping the Rosacea therapeutics market growth?

Research Methodology

The Rosacea therapeutics market has been estimated based on supply-demand approach. The market was first calculated based on incidence and diagnosis rate, conducted in different region/countries. Other qualitative factors analyzed during the estimation include treatment rates for Rosacea therapeutics, recurrence rate and others. This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases). The research study on Rosacea therapeutics market also includes top trends and macro as well as micro economic factors shaping the Rosacea therapeutics market. With this approach, the report on Rosacea therapeutics market anticipates the industry attractiveness of every major segment in Rosacea therapeutics over the forecast period.

Company Profiles

  • Foamix Pharmaceuticals Ltd.
  • SONOMA PHARMACEUTICALS, INC.
  • Allergan plc
  • Pfizer Inc.
  • Nestlé Skin Health (Galderma S.A.)
  • Bayer AG
  • Mylan N.V.
  • Janssen Pharmaceuticals, Inc.
  • Teva Pharmaceuticals Company
  • Others.
Back To Top